New dengue vaccine shows promise in japan trial

NCT ID NCT06741683

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a dengue vaccine (TDV) in 187 healthy Japanese volunteers aged 4 to 60. Participants received two shots three months apart. The main goal was to see if the vaccine triggers an immune response against all four types of dengue virus. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dengue tetravalent vaccine (live, attenuated) also known as TAK-003

What this could lead to

If successful, this vaccine could help prevent dengue fever in people living in or traveling to Japan.

What could go wrong

This is a relatively small, completed trial focused on immune response, not actual disease prevention. Results may not guarantee protection in real-world outbreaks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OKURA Otolaryngology Clinic

    Toshima-ku, Tokyo, Japan

  • PS Clinic

    Fukuoka, Fukuoka, Japan

  • Saitama City Hospital

    Saitama-shi, Saitama, Japan

  • Sumida Hospital

    Sumida-ku, Tokyo, Japan

  • Tamura Clinic

    Tokyo, Japan